Trial Profile
A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ) ) Versus Triple Therapy Regimen (Reiferon Retard + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard + Ribavirin) in the Treatment of Naive Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alfacalcidol (Primary) ; Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 20 Jul 2013 New trial record